
|Articles|November 24, 2021
GxP regulated industry assessments of SoftMax Pro Software v2
Author(s)Molecular Devices
This document outlines references to 21 CFR Part 11 and EudraLex Annex 11 and how they apply to the implementation of SoftMax Pro GxP Data Acquisition and Analysis Software in regulated environments.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
5